UTHR CEO exercises 8,000 options, sells 8,000 shares via 10b5-1

United Therapeutics (UTHR) reported insider activity by its Chairperson & CEO.

Rhea-AI Filing Summary

United Therapeutics (UTHR) reported insider activity by its Chairperson & CEO. Under a pre-arranged Rule 10b5-1 plan, the executive exercised 8,000 stock options at $120.26 on 10/21–10/22/2025 and sold 8,000 shares in related transactions at weighted average prices ranging from $420.00 to $432.20. The plan continues until the earlier of exhaustion of a tranche of 294,000 options expiring 03/15/2026 or 12/31/2025.

After these trades, direct holdings were 130 shares. Indirect holdings were disclosed as 166 shares by spouse and trust positions of 324,518; 258,117; 45,596; and 15,962 shares. Remaining stock options beneficially owned were 162,000 with an expiration of 03/15/2026.

Insider Trade Summary

Exercise and Sale: 8,000 shares ($2.44M approx. pre-tax spread)

Exercise and Sale 16 txns

Insider ROTHBLATT MARTINE A

Role Chairperson & CEO

Sold 8,000 shs ($3.40M)

Approx. gross sale proceeds $3.40M

Approx. exercise cost $962K

Approx. pre-tax spread $2.44M

Type	Security	Shares	Price	Value
Exercise	Stock Option	4,000	$0.00	$0.00
Exercise	Common Stock	4,000	$120.26	$481K
Sale	Common Stock	634	$420.4701	$267K
Sale	Common Stock	2,200	$422.1505	$929K
Sale	Common Stock	1,166	$423.0686	$493K
Exercise	Stock Option	4,000	$0.00	$0.00
Exercise	Common Stock	4,000	$120.26	$481K
Sale	Common Stock	1,088	$425.3831	$463K
Sale	Common Stock	1,412	$426.1843	$602K
Sale	Common Stock	1,000	$430.3536	$430K
Sale	Common Stock	500	$432.20	$216K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 162,000 contracts (Direct); Common Stock — 130 shares (Direct); Common Stock — 166 shares (Indirect, by Spouse); Common Stock — 644,193 shares (Indirect, by Trust)

Footnotes (11)

1. F1. This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025.
2. F10. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
3. F11. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
4. F2. This transaction was executed in multiple trades at prices ranging from $424.75 to $425.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. F3. This transaction was executed in multiple trades at prices ranging from $425.94 to $426.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. F4. This transaction was executed in multiple trades at prices ranging from $430.14 to $430.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. F5. This transaction was executed in multiple trades at prices ranging from $420.00 to $420.715. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. F6. This transaction was executed in multiple trades at prices ranging from $421.75 to $422.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. F7. This transaction was executed in multiple trades at prices ranging from $423.06 to $423.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. F8. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
11. F9. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did UTHR's CEO report on Form 4?

The executive exercised 8,000 stock options at $120.26 and sold 8,000 shares on 10/21–10/22/2025 under a Rule 10b5-1 plan.

What prices were the UTHR shares sold for in the reported trades?

Weighted average sale prices ranged from $420.00 to $432.20 across multiple trades on 10/21 and 10/22/2025.

How many UTHR shares does the CEO hold directly after the transactions?

Direct holdings were 130 shares after the reported transactions.

What indirect UTHR holdings were disclosed for the CEO?

Indirect holdings include 166 shares by spouse and trusts holding 324,518; 258,117; 45,596; and 15,962 shares.

How many UTHR stock options remain beneficially owned by the CEO?

162,000 stock options remain beneficially owned, with an expiration date of 03/15/2026.

What are the key terms of the CEO’s 10b5-1 trading plan?

The plan runs until the earlier of the exhaustion of a 294,000-option tranche expiring 03/15/2026 or 12/31/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/22/2025 - 05:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairperson & CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/21/2025		M(1)		4,000	A	$120.26	4,130	D
Common Stock	10/21/2025		S(1)		1,088	D	$425.3831(2)	3,042	D
Common Stock	10/21/2025		S(1)		1,412	D	$426.1843(3)	1,630	D
Common Stock	10/21/2025		S(1)		1,000	D	$430.3536(4)	630	D
Common Stock	10/21/2025		S(1)		500	D	$432.2	130	D
Common Stock	10/22/2025		M(1)		4,000	A	$120.26	4,130	D
Common Stock	10/22/2025		S(1)		634	D	$420.4701(5)	3,496	D
Common Stock	10/22/2025		S(1)		2,200	D	$422.1505(6)	1,296	D
Common Stock	10/22/2025		S(1)		1,166	D	$423.0686(7)	130	D
Common Stock								166	I	by Spouse
Common Stock								324,518	I	by Trust(8)
Common Stock								258,117	I	by Trust(9)
Common Stock								45,596	I	by Trust(10)
Common Stock								15,962	I	by Trust(11)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$120.26	10/21/2025		M(1)			4,000	03/15/2016	03/15/2026	Common Stock	4,000	$0.00	166,000	D
Stock Option	$120.26	10/22/2025		M(1)			4,000	03/15/2016	03/15/2026	Common Stock	4,000	$0.00	162,000	D

Explanation of Responses:

1. This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $424.75 to $425.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $425.94 to $426.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $430.14 to $430.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $420.00 to $420.715. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $421.75 to $422.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $423.06 to $423.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

9. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

10. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

11. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	10/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.